Urispas review

Urispas is commonly used to treat over active bladder, frequent urination, incontinence, night time urination, painful urination, and difficult urination, and can be generically prescribed as flavoxate. Urispas works by relaxing the muscles which spasm in the urinary tract.

Urispas is not appropriate for everyone and should not be prescribed without first assessing a thorough medical history. Patients with a medical history which includes bleeding in the stomach, blockage of the urinary tract, or blockage of the intestines should not use Urispas, or might require careful monitoring while undergoing drug therapy with this medication, depending on the severity of the condition. Urispas has not been evaluated for use in children under the age of 12.

The American Food and Drug Administration rated Urispas as a pregnancy risk category B, meaning that this medication is not expected to cause harm or birth defects in an unborn fetus. It has yet to be determined whether or not Uriapas will pass through the mother’s breast milk and affect a nursing infant. Caution is warranted when prescribing this medication to women who are pregnant or nursing, and should only be prescribed when the benefits clearly outweigh the risks.

There is a risk of side effects associated with Urispas, some more severe than others. If a patient experiences a serious side effect or an allergic reaction while taking Urispas, they should seek immediate medical assistance. AN allergic reaction is likely to present with symptoms which include hives, difficulty breathing, and facial swelling (swelling of the lips, mouth, tongue, or throat.) Other serious side effects which require immediate emergency medical care include an irregular heart rate or a fast heart rate.

Other side effects, which are much less serious, are likely to include difficulty urinating, dry mouth, nausea, vomiting, dizziness, drowsiness, lightheadedness, nervousness, blurry vision, enlarged pupils, confusion, or dry eyes. These side effects do not require emergency medical attention, although patients should routinely report all side effects to the prescribing physician. Physicians should encourage patients to report all side effects.

Urispas should only be taken as it has been prescribed. Should the patient forget to take a dose, the dose should be taken as soon as it is remembered unless it is almost time for the next scheduled dose. Taking doses too close together or doubling up on medication to make up for a missed dose is likely to cause an overdose. In the event of an overdose of Urispas, the patient should seek medical attention right away. An overdose may present with symptoms such as irritability, tremors, nausea, vomiting, fast heart rate, restlessness, seizures, delirium, hallucinations, flushing, coma, and death.

There is a risk presented by Urispas of drug interactions when taking other medications at the same time. Patients should always check with their prescribing physician before taking any new medications, including over the counter medications and herbal supplements. Medications with known interactions include antidepressants, antihistamines, cold medications, and other medication which enhance drowsiness such as narcotic pain relievers, muscle relaxants, and sedatives.

Patients should avoid becoming overheated as Urispas reduces the body’s ability to sweat and increases the risk of heat stroke and other heat related illnesses. Alcoholic beverages are likely to cause a worsening of side effects and should be avoided while undergoing drug therapy with Urispas. Sudden onset dizziness or lightheadedness may occur when taking Urispas, patients should be encouraged to use caution when driving a car or operating machinery.

Urispas has the following structural formula:

Chemical structure of urispas

• Molecular formula of urispas is C24H25NO4
• Chemical IUPAC Name is 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenyl-chromene-8-carboxylate
• Molecular weight is 391.46 g/mol
Urispas available : 100mg tablets

Generic name: Flavoxate

  Your Urispas review